Source comparison
TB-500 Dosage Comparison by Protocol Type
Acute Loading 2.5–5mg Twice weekly (e.g., Mon/Thu) 4–6 weeks Achieves steady-state VEGF and MMP upregulation; sustains actin sequestration to promote cell migration without clearance gaps Optimal for initiating tissue repair cascades; doses above 5mg show no a
This comparison does not assign a generated winner or score.
- Acute Loading
- 2.5–5mg
- Twice weekly (e.g., Mon/Thu)
- 4–6 weeks
- Achieves steady-state VEGF and MMP upregulation; sustains actin sequestration to promote cell migration without clearance gaps
- Optimal for initiating tissue repair cascades; doses above 5mg show no additional receptor engagement
- Maintenance
- 2mg
- Once weekly
- Ongoing (8–12 weeks typical)
- Preserves established angiogenic pathways and fibroblast activity without oversaturation; cost-effective sustain phase
- Appropriate after loading phase; prevents regression while avoiding unnecessary receptor exposure
- Mega-Dose (Anecdotal)
- 10mg+
- Twice weekly or more
- Variable
- No validated mechanism. Exceeds receptor saturation thresholds identified in cell culture and animal models
- Not supported by pharmacodynamic data; financial waste with no evidence of superior outcomes
- Single High-Dose
- 7.5–10mg
- Once at injury onset
- One-time or infrequent
- Theory: rapid actin binding limits fibrotic scar formation in acute trauma window (unproven in humans)
- Speculative; lacks controlled human trial data; standard loading protocols more reliable